What homocysteine is and why it accumulates
Homocysteine is a sulfur-containing amino acid produced as an intermediate in the metabolism of methionine, an essential amino acid found in protein-rich foods. Under normal circumstances, homocysteine is rapidly recycled through one of two pathways: remethylation back to methionine (requiring folate and B12) or transsulfuration to cysteine (requiring B6)[1].
When either pathway is impaired — due to nutrient deficiency, genetic variants, or kidney dysfunction — homocysteine accumulates in the blood. This is called hyperhomocysteinemia: mild (15-30 mcmol/L), moderate (30-100 mcmol/L), or severe (>100 mcmol/L, rare, usually genetic).
The cardiovascular connection
The link between homocysteine and cardiovascular disease was first proposed by Kilmer McCully in 1969, based on the observation that children with severe genetic homocysteine disorders developed premature atherosclerosis[2]. Since then, dozens of prospective studies have confirmed that elevated homocysteine is an independent risk factor for coronary heart disease, stroke, peripheral vascular disease, and venous thromboembolism[3].
A meta-analysis of prospective studies found that each 5 mcmol/L increase in homocysteine was associated with approximately a 20% increase in coronary heart disease risk and a 50% increase in stroke risk, independent of traditional risk factors[4].
How does homocysteine cause damage?
The mechanisms are multiple and well-characterized: endothelial dysfunction (damage to the inner lining of blood vessels), increased oxidative stress, promotion of thrombosis (blood clotting), stimulation of smooth muscle cell proliferation in arterial walls, and impaired nitric oxide bioavailability[5].
The B-vitamin triad: B12, folate, B6
The three B-vitamins that control homocysteine metabolism are the most common modifiable causes of elevation:
Folate (vitamin B9) is required by the enzyme MTHFR to produce 5-methyltetrahydrofolate, the methyl donor that converts homocysteine back to methionine via the enzyme methionine synthase. Folate deficiency is the most common nutritional cause of elevated homocysteine[6].
Vitamin B12 (cobalamin) is a cofactor for methionine synthase. Without adequate B12, the remethylation pathway stalls and homocysteine accumulates — even if folate is adequate. This is why B12 deficiency often presents with elevated homocysteine before serum B12 drops below the standard reference range. Homocysteine is actually a more sensitive marker of functional B12 deficiency than serum B12 itself[7].
Vitamin B6 (pyridoxine) is a cofactor for the transsulfuration pathway, which converts homocysteine to cysteine. B6 deficiency is a less common cause of elevated homocysteine than B12 or folate deficiency, but it is clinically relevant in older adults and in those with high protein intake[8].
MTHFR: the genetic variable
The MTHFR gene encodes the enzyme methylenetetrahydrofolate reductase, which converts dietary folate into its active form (5-methyltetrahydrofolate). Two common variants affect enzyme function[9]:
C677T: The most clinically significant variant. Heterozygous carriers (CT genotype, approximately 40% of the population) have ~35% reduced enzyme activity. Homozygous carriers (TT genotype, approximately 10-15% of the population) have ~70% reduced activity. The TT genotype is associated with 25% higher homocysteine on average.
A1298C: Less clinically significant. Homozygous carriers (CC genotype) have modestly reduced enzyme activity. The compound heterozygous state (one copy of each variant) can also have clinical relevance.
| MTHFR C677T genotype | Population frequency | Enzyme activity | Effect on homocysteine |
|---|---|---|---|
| CC (normal) | ~45% | 100% | None |
| CT (heterozygous) | ~40% | ~65% | +10-15% (mild) |
| TT (homozygous) | ~10-15% | ~30% | +20-30% (moderate) |
The important nuance: MTHFR variants only significantly raise homocysteine when folate status is suboptimal. With adequate folate intake — particularly methylfolate (5-MTHF), which bypasses the impaired enzyme — even TT homozygotes can maintain normal homocysteine levels[10].
The trial controversy: does lowering homocysteine help?
This is the elephant in the room. If elevated homocysteine causes cardiovascular disease, then lowering it should reduce events. Large randomized trials tested this hypothesis — and the results were mixed.
The HOPE-2 trial (5,522 patients with vascular disease) found that B-vitamin supplementation reduced homocysteine by 25% but did not reduce overall cardiovascular events. However, it did reduce stroke risk by 25%[11].
A meta-analysis of 12 randomized trials involving over 47,000 participants concluded that folic acid supplementation reduced stroke risk by 10-20% but had no significant effect on coronary events or overall mortality[12].
Why the disconnect? Several explanations have been proposed: the trials enrolled patients who already had cardiovascular disease and were on aggressive medication (statins, antiplatelet agents), homocysteine lowering may be more effective for primary prevention, the damage from chronically elevated homocysteine may not be fully reversible, and the trials may have been too short to show effects on slowly progressing atherosclerosis.
Beyond the heart: brain, bone, pregnancy
Elevated homocysteine is also associated with cognitive decline and dementia (particularly Alzheimer's disease), osteoporotic fractures (homocysteine interferes with collagen cross-linking in bone), neural tube defects in pregnancy (this is why folic acid supplementation is universal for pregnant women), and depression.
What to do with your results
- Target below 10 mcmol/L. While the standard range extends to 15, cardiovascular risk increases progressively above 10. Many clinicians consider below 8 mcmol/L optimal.
- If elevated, check B12 and folate first. These are the most treatable causes. Request serum B12, folate (or red cell folate), and MMA (methylmalonic acid, a more specific marker of B12 function).
- Supplement with methylfolate and methylcobalamin rather than folic acid and cyanocobalamin. The methylated forms bypass potential MTHFR limitations and are directly usable by the body. Typical doses: 400-800 mcg methylfolate, 500-1000 mcg methylcobalamin, 25-50 mg B6.
- Consider MTHFR testing if homocysteine remains elevated despite adequate B-vitamin supplementation. This guides dosing and form selection.
- Retest in 6-8 weeks after starting supplementation. Homocysteine responds quickly to B-vitamin repletion — a significant drop confirms the diagnosis and adequacy of treatment.
- Rule out other causes: kidney disease (eGFR < 60), hypothyroidism, medications (methotrexate, phenytoin, metformin), and very high protein intake can all raise homocysteine.